An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Enfortumab vedotin (Primary) ; Docetaxel; Paclitaxel; Vinflunine
- Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 09 Jul 2018 According to an Astellas Pharma media release, first has been dosed in this trial.
- 30 Apr 2018 Status changed from not yet recruiting to recruiting.
- 16 Mar 2018 Status changed from planning to not yet recruiting.